SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Booker T. Washington

PatientBooker T. Washington
Date of birth1967-04-05
IdentifiersMRN HR-NI017-SYN; SSN (made up) 000-17-2284
Document date2026-10-26
AuthorLorraine Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month blood pressure and chronic kidney disease review. [S]

History of Present Illness

Mr. Washington returns for his six-month review. The back strain in August cleared in about ten days, and he has taken no NSAIDs since. His home readings run in the high 110s to low 120s systolic, with no dizziness on standing. His headaches have not returned, and his concentration is better than in the spring, though he still tires by evening on travel days. He walks 20 to 30 minutes on most days at home. He gets up once a night to urinate and has had no genital symptoms on dapagliflozin. He received the influenza and first zoster vaccines last month. He asked last month to learn more about what would happen if his kidney function fell further. [S]

ElementDetail
Interval historyAugust back strain resolved; no NSAIDs since
Home blood pressureHigh 110s to low 120s systolic; no dizziness
SymptomsNo headaches; concentration better; tires on travel days
ActivityWalking 20 to 30 minutes on most days
Patient questionWhat happens if his kidney function falls further

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by evening on travel days; weight stable
EyesNegativeNo new blurring or loss of vision
CardiovascularNegativeNo chest pain, palpitations, or ankle swelling
GenitourinaryNegativeUp once a night; no dysuria or genital symptoms
MusculoskeletalNegativeBack pain resolved
NeurologicalNegativeNo headache or dizziness on standing
PsychiatricNegativeMood steady; PHQ-9 score 2

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04activeS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04 to 2026-05-11completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route2026-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-26Body height170cmS
2026-10-26Body weight70.5kgS
2026-10-26Body mass index (BMI) [Ratio]24.4kg/m2S
2026-10-26Systolic blood pressure118mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate72/minS
2026-10-26Respiratory rate14/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-26Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-10-26Urea nitrogen [Mass/volume] in Serum or Plasma34mg/dL6-24 mg/dLHighS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma2.3mg/dL0.74-1.35 mg/dLHighS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M32mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-10-26Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-10-26Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
2026-10-26Phosphate [Mass/volume] in Serum or Plasma4mg/dL2.5-4.5 mg/dLNormalS
2026-10-26Parathyrin.intact [Mass/volume] in Serum or Plasma78pg/mL15-65 pg/mLHighS
2026-10-26Hemoglobin [Mass/volume] in Blood12.8g/dL13.2-16.6 g/dLLowS
2026-10-26Albumin/Creatinine [Mass Ratio] in Urine240mg/g<=30 mg/gHighS
2026-10-26Kidney failure 2-year risk [Likelihood] by KFRE6.5%S
2026-10-26Kidney failure 5-year risk [Likelihood] by KFRE18.8%S
2026-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S

Physical Exam

Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Blood pressure118/76 mmHg, the average of two seated readings after five minutes' rest; no fall on standing
HeartRegular rhythm, rate 72; soft S4
LungsClear
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150activeconfirmed I12.9S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R.
Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosisactiveconfirmed N18.32S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease.
Hypertensive retinopathy, both eyes, without papilledemaactiveconfirmed H35.033S — Synthetic funduscopic finding that echoes the documented failing vision.
Mild anemia of chronic kidney disease, iron replete; monitoractiveconfirmed D63.1S — Synthetic finding from the baseline hemoglobin and iron studies.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
Acute lumbar muscle strain after lifting, resolved without NSAIDs or imagingresolvedconfirmed S39.012AS — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panelWith each eGFR drawCompleted todayPotassium 4.5, bicarbonate 23, creatinine 2.3 mg/dL, eGFR 32
LaboratoryeGFR and urine albumin-creatinine ratioAbout 3 times a year for G3b A3Completed todayeGFR 32; urine albumin-creatinine ratio 240 mg/g, down 71 percent from 820. The third pair since diagnosis, on schedule
LaboratoryCalcium, phosphate, and PTHEvery 6 to 12 months in G3bCompleted todayCalcium 9.2, phosphate 4.0, PTH 78 pg/mL (down from 92)
Laboratory25-hydroxyvitamin DOnce at baselineDeferredNot drawn at diagnosis or with today's calcium, phosphate, and PTH, a deviation from the protocol. PTH is falling with normal calcium and phosphate, so no harm is evident. Corrective action: added to the next draw
LaboratoryHemoglobinAt least yearly in G3Completed today12.8 g/dL, stable
LaboratoryIron studiesAt anemia diagnosis; repeat with a fall in hemoglobin or on an ESANot indicatedIron replete in May; hemoglobin stable and no ESA
SurveyKidney failure risk equation, 2 and 5 yearsYearly in G3 to G5Completed today6.5 percent at 2 years and 18.8 percent at 5 years; the 5-year risk is above the 3 to 5 percent referral threshold, confirming nephrology care
ReferralNephrology5-year kidney failure risk of 3 to 5 percent or more, or persistent A3 albuminuriaUp to dateSeen in May; today's results, risk scores, and his question about kidney failure options sent ahead of his next nephrology review
LaboratoryUrinalysis with microscopyWith a change in statusNot indicatedNo change in status: albuminuria fell by 71 percent and eGFR is stable. The missing baseline urinalysis is recorded as a deviation at the one-week visit
LaboratoryCystatin CWhen a decision hinges on a more accurate eGFRNot indicatedNo dosing or referral decision depends on it now
LaboratoryAlkaline phosphataseYearly in G4 to G5Not indicatedeGFR 32 is stage G3b
LaboratoryLipid panelOnce at diagnosis in chronic kidney disease; yearly when stable in the lipid monographNot indicatedNo repeat LDL, per the CKD monograph and KDIGO; a deliberate departure from the lipid monograph
LaboratoryHbA1cYearly in hypertensionUp to date5.4 percent in May; glucose 93 mg/dL today
ExaminationStandardized office blood pressureEvery visit; target systolic below 120 when toleratedCompleted today118/76 mmHg; systolic target met
ExaminationWeight, BMI, and cardiac auscultationEvery visitCompleted today70.5 kg, BMI 24.4; soft S4
ExaminationFunduscopic examinationYearly in chronic hypertensionUp to dateDilated examination in May; unchanged on undilated examination last month; next in May
ImagingECG and echocardiogramAt diagnosis; repeat as clinically indicatedNot indicatedLeft ventricular hypertrophy documented in May; no new symptoms
ExaminationPeripheral pulses and ankle-brachial indexEvery 2 to 3 years at 65 or older or with a smoking historyNot indicatedAge 59 and a never smoker
Survey10-year ASCVD risk estimateYearly in hypertensionNot indicatedAlready on a statin for the chronic kidney disease indication, so the estimate would not change treatment
SurveyPHQ-9Yearly in hypertensionCompleted todayScore 2
Medication safetyMedication review: NSAID avoidance and kidney dosingEvery visitCompleted todayNo NSAIDs since the August naproxen; the pharmacy flag is in place
Medication safetyVaccination reviewYearly in chronic kidney diseaseDueInfluenza and zoster dose 1 given last month; zoster dose 2 due from next month; COVID-19 and RSV vaccines were discussed last month
Self-managementHome blood pressure log, sodium below 2 g a day, and activityEvery visitCompleted todayWalking about 120 minutes a week; goal 150. Sodium plan for travel reinforced

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)

Follow-up: PSA and hepatitis C and HIV screening from the preventive plan added to today's draw; results reviewed when they return. Zoster vaccine dose 2 from next month. Blood pressure and kidney review in about four months with eGFR, urine albumin, a basic metabolic panel, and vitamin D. Nephrology review. [S]